Feebris provides a mobile health platform powered by artificial intelligence (AI). It enables non-medical users to diagnose and monitor complex health conditions in the community. The company was founded in 2017 and is based in London, United Kingdom.
Feebris's Product Videos
Feebris's Products & Differentiators
The core of our AI-powered platform is the proprietary AI-guided examination & triage engine, which translates data from off-the-shelf point-of-care sensors into reliable and actionable clinical insights. The platform has three major components: Mobile App: connects wirelessly to medical sensors (e.g. pulse oximeters, digital stethoscopes) and guides a non-clinical user through AI algorithms for quality control, symptom extraction, and deterioration triage. Clinical Web Portal: clinical teams review, prioritize, and distribute deterioration response, accelerating treatment access. Population Health Management Web Portal: population health teams review insights informing resource allocation and risk management.
Research containing Feebris
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Feebris in 1 CB Insights research brief, most recently on Aug 9, 2023.
Expert Collections containing Feebris
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Feebris is included in 3 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.
Latest Feebris News
Nov 16, 2023
☕ Your morning summary of digital health news, information and events to know about if you want to be “in the know”. 👇 News 🤩 The Feebris AI-guided virtual care platform has received the maximum score of 100 on usability and accessibility in a DTAC assessment conducted by NHS England. Launched in beta in 2020 and officially in February 2021, the Digital Technology Assessment Criteria (DTAC) sets out the national baseline for standards that all digital health and care solutions deployed in the system have to meet, divided into five categories: Clinical safety (pass/fail); Data protection (pass/fail); Technical security (pass/fail); Interoperability (pass/fail); Usability and accessibility (the only scored section). The framework brings together existing legislation and best practice in each of the five categories, being introduced for use by organisations to assess digital health and care tools either during procurement or as part of a due diligence process. The Feebris AI-guided virtual care platform is currently deployed in over 100 Integrated Care System (ICS) sites across the country. 🤝 Tunstall Healthcare and the University of Edinburgh have signed a Memorandum of Understanding at an event in Edinburgh City Chambers. The partnership aims to accelerate the delivery of innovative solutions in digital care, by facilitating the collaborative exchange of academic and industry expertise to harness the growing potential of data- and AI-led innovations. Under the agreement, the two organisations will work on the development and deployment of digital tools and techniques for telecare. It is anticipated that the range and depth of research conducted through the partnership will also support larger, multi-partner collaborations focused on the development of innovations in digital health. 🦵 A project to support patients with their hip and knee replacement recovery using wearable technology has been shortlisted for a national innovation award. The Orthopaedic Clinical Research team at the Norfolk and Norwich University Hospital and the University of East Anglia (UEA) Health Economics team have been shortlisted with Dynamic Metrics Ltd for the Collaborate to Innovate Awards. The GaitSmart study ran at NNUH between 2020 and 2022 to develop and test a system to study mobility and improve a patient’s gait after a joint replacement. 🧑⚕️ Following the success of the groundbreaking Circular Ring Pro, Circular , pioneers of smart ring technology, is excited to unveil the Circular Ring Slim, the thinnest, and lightest, most intuitive smart ring in the world and the first to incorporate haptic navigation and alerts. Paired with Kira+, Circular’s powerful AI wellness assistant, the sleek Circular Ring Slim assesses seven biometrics and 142 derived markers 24/7 to help people sleep better and live healthier lives. By optimising physical activities and maintaining mental wellness it is making personalised, preventative health a reality. 👁 Injectsense Inc ., a sensor-enabled digital health company, and sister company Injectpower , a developer of ultra-miniature solid-state microbatteries for medical applications, today announced combined funding of $9.4 million to bring highly integrated autonomous implantable devices – smaller than a grain of rice — to production. The implantable sensors, which monitor key indicators over decades, offer a disruptive capability at a time when most diagnostic tools are a mere static snapshot. Physiological markers are typically dynamic and vary widely over a 24-hour period. Such is the case with glaucoma, where intraocular pressure (IOP) is measured in the doctor’s office during daylight hours. Injectsense sensors measure IOP continuously, even during sleep, when pressure can spike significantly and cause vision loss over the long term. ❓ Did you know that? AI and chatbots like GPT (Generative Pre-trained Transformer) are rapidly evolving and shaping the way we access information. Although these advancements have demonstrated benefits in various areas around health, it is essential to be cautious, particularly when seeking medical advice. This often draws people seeking information on taboo health topics, where societal stigmas or personal discomfort may restrict people from speaking to professionals. According to a survey by Plan International UK , 700,000 people between the ages of 16-25 rely on AI chatbots for advice on sexual health. It becomes appealing as it is discreet and non-judgemental for sensitive health issues. However, taboo health topics often require complex understanding of people’s experiences and emotions, which AI can struggle to comprehend. 📖 What we’re reading District councils have statutory powers over service areas including planning, housing, benefits, and leisure and green spaces, which affect many of the most significant determinants of health. Around 40 per cent of the population of England live in a district council area. The King’s Fund interviewed district council officers and integrated care board (ICB) staff in four sites from around England to better understanding the current relationships between local government and ICBs, what good practice looks like, what enables it and the outcomes it produces. 🚨 This week’s events
Feebris Frequently Asked Questions (FAQ)
When was Feebris founded?
Feebris was founded in 2017.
Where is Feebris's headquarters?
Feebris's headquarters is located at Accelerator London, London.
What is Feebris's latest funding round?
Feebris's latest funding round is Incubator/Accelerator - III.
How much did Feebris raise?
Feebris raised a total of $120K.
Who are the investors of Feebris?
Investors of Feebris include NHS Innovation Accelerator, Digital Health London, Social Starts, TechForce19, 24Haymarket and 5 more.
Who are Feebris's competitors?
Competitors of Feebris include Current Health and 2 more.
What products does Feebris offer?
Feebris's products include Feebris.
Who are Feebris's customers?
Customers of Feebris include Northumbria Foundation Trust and North East London CCG.
Compare Feebris to Competitors
Myia provides a data-driven virtual care platform for optimizing virtual healthcare delivery. Its solutions include remote patient monitoring, predictive analytics, process control, and workflow orchestration. It serves clinicians, patients, and healthcare providers. It was founded in 2017 and is based in San Francisco, California.
NanoVation is a medical devices startup company that focuses on the healthcare sector, specifically in the domain of respiratory monitoring. The company offers innovative solutions for remote monitoring and disease management of lung diseases and chronic respiratory conditions, providing a reliable solution for monitoring various chronic respiratory diseases, including COPD and asthma. Their patented technology can identify subtle changes in a patient's respiratory condition, enabling healthcare professionals to take proactive measures and prevent patient’s exacerbation and unnecessary hospitalizations. It was founded in 2014 and is based in Haifa, Israel.
Qlarity Imaging is a company that focuses on the development of artificial intelligence software in the healthcare sector. The company's main product is a decision support tool that assists radiologists in improving the diagnosis of breast abnormalities by analyzing data from MR images. The company primarily serves the healthcare industry. It was founded in 2018 and is based in Chicago, Illinois. Qlarity Imaging operates as a subsidiary of Paragon Biosciences.
Sensome focuses on the development of sensor technology for the healthcare sector. The company's main offering is a sensor technology to transform invasive medical devices into connected healthcare devices, using impedance-based micro-sensors and machine learning algorithms to identify biological tissues with high predictive reliability. This technology is primarily used in the medical fields such as interventional cardiology and oncology. Sensome was formerly known as Insent. It was founded in 2014 and is based in Massy, France.
Proscia focuses on the development of software for the pathology sector. The company's main offerings include a digital pathology platform and AI-powered applications that facilitate routine pathology operations, research breakthroughs, and patient outcomes. Proscia primarily serves the life sciences and diagnostics sectors. It was founded in 2014 and is based in Philadelphia, Pennsylvania.
TRIBVN Healthcare is a company focused on the digital transformation of cancer diagnosis within the healthcare sector. The company offers innovative solutions for the management, analysis, and sharing of cellular images, leveraging artificial intelligence technologies to support diagnostic decision-making and scientific evaluation. Its primary customers include diagnostic laboratories, pharmaceutical companies, and biotech organizations. It was founded in 2011 and is based in Paris, France.